Search Results
Jan 01, 2026, 09:00 ET ChemPartner Unveils Updated Visual Identity and Digital Experience Reflecting Its Reputation as a Trusted Biopharma Partner
manufacturing services including chemistry and biologics discovery, pharmacology, DMPK, and exploratory toxicology and development and manufacturing CDMO services. Shanghai ChemPartner serves a diverse global client base, with laboratories, business offices, and representatives in the U.S., Europe, China,
More news about: ChemPartner
Dec 22, 2025, 16:00 ET mAbxience und Amneal geben FDA-Zulassung für Denosumab-Biosimilars unter Bezugnahme auf Prolia® und XGEVA® bekannt
Bereich Auftragsentwicklung und Auftragsfertigung (CDMO) spezialisiert und nutzt fortschrittliche Technologien und innovative Plattformen, um integrierte Fertigungslösungen anzubieten. Weitere Informationen zu mAbxience, unseren Biosimilars und unserem CDMO-Geschäft finden Sie auf unserer Website (
More news about: mAbxience
Dec 22, 2025, 16:00 ET mAbxience e Amneal annunciano l'approvazione da parte della FDA dei biosimilari di denosumab con riferimento a Prolia® e XGEVA®
di Contract Development and Manufacturing Organization (CDMO), utilizzando tecnologie avanzate e piattaforme innovative per fornire soluzioni di produzione integrate. Per ulteriori informazioni su mAbxience, i nostri biosimilari e l'attività CDMO, visitate il nostro sito web (
More news about: mAbxience
Dec 22, 2025, 16:00 ET mAbxience y Amneal anuncian la aprobación de la FDA de biosimilares de denosumab referidos a Prolia® y XGEVA®
Desarrollo y Fabricación por Contrato (CDMO, por sus siglas en inglés), utilizando tecnología avanzada y plataformas innovadoras para ofrecer soluciones de fabricación integradas. Para más información sobre mAbxience, sus biosimilares o el área negocio de CDMO, visite el sitio web
More news about: mAbxience
Dec 22, 2025, 16:00 ET mAbxience et Amneal annoncent l'autorisation par la FDA des biosimilaires du denosumab référencés Prolia® et XGEVA®
de développement et de fabrication sous contrat (CDMO), utilisant des technologies de pointe et des plateformes innovantes pour fournir des solutions de fabrication intégrées. Pour plus d'informations sur mAbxience, nos biosimilaires et nos activités CDMO, veuillez consulter notre site web (
More news about: mAbxience
Dec 22, 2025, 09:00 ET MCB Group Unveils Daily Sports Nutrition Innovations at SupplySide Global 2025, Spotlighting Creatine, MCT, and Plant-Based Protein
ingredients, has further streamlined its operations into a full CDMO private-label provider, showcasing a range of trend-driven branded ingredients and turnkey total solutions at SupplySide Global 2025, aimed
More news about: MCB (Ming Chyi Biotech)
Dec 21, 2025, 17:43 ET Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
Dec. 21, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human
More news about: Samsung Biologics
Dec 19, 2025, 00:00 ET MEDIPOST Announces the Exclusive Commercialization License Agreement with Teikoku Seiyaku for Knee Osteoarthritis Treatment CARTISTEM® in Japan
and clinical development of allogeneic cell therapy pipelines, cord blood banking, and cell and gene therapy contract development and manufacturing (CDMO) business portfolios. MEDIPOST successfully commercialized the world's first regulatory-approved (2012) allogeneic human umbilical cord blood-derived
More news about: MEDIPOST
Dec 18, 2025, 18:07 ET AtomVie Global Radiopharma conclut un accord de fourniture avec Ionetix Corporation pour accélérer le développement de la radiothérapie à l'Ac-225
/PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), une organisation mondiale de développement et de fabrication à façon de produits radiopharmaceutiques (CDMO) spécialisée dans la fabrication BPF et l'approvisionnement clinique, a le plaisir d'annoncer un partenariat stratégique avec Ionetix Corporation (Ionetix)
More news about: AtomVie Global Radiopharma Inc.
Dec 18, 2025, 11:33 ET AtomVie Global Radiopharma firma un acuerdo de suministro con Ionetix Corporation
2025 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), una organización global de desarrollo y fabricación por contrato (CDMO) de radiofármacos especializada en la fabricación según las buenas prácticas de fabricación (GMP) y el suministro clínico, se complace en anunciar una
More news about: AtomVie Global Radiopharma Inc.
Dec 18, 2025, 11:32 ET AtomVie Global Radiopharma schließt Liefervertrag mit Ionetix Corporation zur Beschleunigung der Entwicklung von Ac-225-Strahlentherapeutika
18. Dezember 2025 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), ein weltweit tätiges Auftragsentwicklungs- und Produktionsunternehmen (CDMO) für Radiopharmazeutika, das sich auf die GMP-konforme Herstellung und klinische Versorgung spezialisiert hat, freut sich, eine strategische Partnerschaft
More news about: AtomVie Global Radiopharma Inc.
Dec 18, 2025, 11:17 ET Minaris and Cell and Gene Therapy Catapult Announce Collaboration to Advance Delivery Methods for Cell and Gene Therapies
Dec. 18, 2025 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Cell and Gene Therapy Catapult (CGT Catapult), an independent technology and innovation organization
More news about: Minaris Advanced Therapies
Dec 18, 2025, 11:08 ET Minaris and Cell and Gene Therapy Catapult Announce Collaboration to Advance Delivery Methods for Cell and Gene Therapies
Dec. 18, 2025 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Cell and Gene Therapy Catapult (CGT Catapult), an independent technology and innovation organization
More news about: Minaris Advanced Therapies
Dec 18, 2025, 08:30 ET AtomVie Global Radiopharma Secures a Supply Agreement with Ionetix Corporation to Accelerate Ac-225 Radiotherapeutics Development
18, 2025 /PRNewswire/ - AtomVie Global Radiopharma (AtomVie), a global radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in GMP manufacturing and clinical supply, is pleased to announce a strategic partnership with Ionetix Corporation (Ionetix) to enhance
More news about: AtomVie Global Radiopharma Inc.
Dec 18, 2025, 08:30 ET AtomVie Global Radiopharma Secures a Supply Agreement with Ionetix Corporation to Accelerate Ac-225 Radiotherapeutics Development
2025 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in GMP manufacturing and clinical supply, is pleased to announce a strategic partnership with Ionetix Corporation (Ionetix) to enhance
More news about: AtomVie Global Radiopharma Inc.
Dec 16, 2025, 11:53 ET Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
industry transitions from boutique R&D operations to scalable bioprocessing infrastructure[1]. Gene and CAR-T therapy demand has driven CDMO partnerships to expand viral vector production and GMP-compliant facilities at unprecedented velocity, overcoming bottlenecks that previously constrained
More news about: Equity Insider
Dec 16, 2025, 10:10 ET Alcami Expands Drug Product Manufacturing Capacity to Meet Growing Demand
Dec. 16, 2025 /PRNewswire/ -- Alcami Corporation, a leading U.S. based contract development and manufacturing organization (CDMO), is proud to announce the GMP readiness of a third sterile fill-finish line at its Research Triangle Park, NC campus. This is the fifth sterile fill-finish
More news about: Alcami
Dec 16, 2025, 09:57 ET INCOG BioPharma Announces $200 Million Expansion, Growing the Team to Nearly 1,000 Employees
Dec. 16, 2025 /PRNewswire/ -- INCOG BioPharma Services, a leading contract development and manufacturing organization (CDMO), today announced another major expansion with an investment of approximately $200 million in its manufacturing facility in Fishers, Indiana. This investment
More news about: INCOG BioPharma
Dec 16, 2025, 08:00 ET PharmaLogic Announces Successful Supply of First Cohort Dosing for Ratio Therapeutics' Phase 1/2 Study of a Novel FAP-Targeted Radiopharmaceutical in Late-Stage Aggressive Sarcomas
PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, announced today that it has successfully supplied the first cohort dosing of Ratio Therapeutics' investigational
More news about: PharmaLogic Holdings Corp
Dec 15, 2025, 17:51 ET Piramal Pharma Solutions dimostra il suo impegno verso l'eccellenza con un eccezionale Net Promoter Score
2025 /PRNewswire/ -- Piramal Pharma Solutions, un'organizzazione leader mondiale nello sviluppo e nella produzione su contratto (CDMO) e parte di Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), ha ottenuto un eccezionale
More news about: Piramal Pharma Solutions
Dec 15, 2025, 17:46 ET Piramal Pharma Solutions demonstriert Engagement für Spitzenleistungen mit hervorragendem Net Promoter Score
2025 /PRNewswire/ -- Piramal Pharma Solutions, ein weltweit führendes Unternehmen für Auftragsentwicklung und -herstellung (CDMO) und Teil von Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), hat einen beeindruckenden
More news about: Piramal Pharma Solutions
Dec 15, 2025, 17:41 ET Piramal Pharma Solutions démontre son engagement envers l'excellence avec un taux de recommandation net exceptionnel
2025 /PRNewswire/ -- Piramal Pharma Solutions, une entreprise de fabrication et de développement en sous-traitance (CDMO) de premier plan mondial, qui fait partie de Piramal Pharma Ltd. (NSE : PPLPHARMA) (BSE :
More news about: Piramal Pharma Solutions
Dec 15, 2025, 08:50 ET Piramal Pharma Solutions demuestra su compromiso con la excelencia con un Net Promoter Score excepcional
15 de diciembre de 2025 /PRNewswire/ -- Piramal Pharma Solutions, organización líder mundial en desarrollo y fabricación por contrato (CDMO) y parte de Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), ha alcanzado un impresionante Net Promoter Score (NPS) de 55 para el año fiscal 2025
More news about: Piramal Pharma Solutions
Dec 15, 2025, 08:00 ET Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group
Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development with integrated CRO/CDMO services. This alignment enables the combined organization to offer a full suite of bioprocessing products, solutions, and services across both research
More news about: Leadgene Biosolutions
Dec 15, 2025, 08:00 ET Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group
Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development with integrated CRO/CDMO services. This alignment enables the combined organization to offer a full suite of bioprocessing products, solutions, and services across both research
More news about: Leadgene Biosolutions